PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'University of Liverpool, 70 Pembroke Place, Liverpool, UK.\', \'Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.\', \'Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK.\', \'Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.\', \'University of Lancaster, Bailrigg, Lancaster, UK.\', \'MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.\', \'Ridgeback Biotherapeutics, 3480 Main Highway, Miami, FL, USA.\', \'Royal Free London NHS Foundation Trust, Pond Street, London, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1093/jac/dkab318
?:hasPublicationType
?:journal
  • The Journal of antimicrobial chemotherapy
is ?:pmid of
?:pmid
?:pmid
  • 34450619
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34450619>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34450619>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all